Trial Profile

Phase II Study of Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary) ; Capecitabine
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms PICTURE

Most Recent Events

24 Oct 2023 Updated survival results presented at the 48th European Society for Medical Oncology Congress.
10 Dec 2022 Results assessing the activity and safety of pyrotinibplus capecitabine only in those patients with trastuzumab-resistant, HER2-positive advanced breast cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
07 Dec 2022 Planned End Date changed from 31 May 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com